Artiva Biotherapeutics, Inc. Common Stock (ARTV NASDAQ) stock market data APIs
$3.4075
0.04(1.2%)
as of November 6, 2025
Try our APIs with
free plan!
Artiva Biotherapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Prev. Close
3.4075
Open
3.4445
High
3.5516
Low
3.3508
52 wk Range
1.47-13.845
Market Cap
84 025 K
Shares Outstanding
24 426 K
EPS
-0.87
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Artiva Biotherapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Artiva Biotherapeutics, Inc. Common Stock data using free add-ons & libraries
Get Artiva Biotherapeutics, Inc. Common Stock Fundamental Data
Artiva Biotherapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -79 073 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Artiva Biotherapeutics, Inc. Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -0.77
Get Artiva Biotherapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Artiva Biotherapeutics, Inc. Common Stock News
New
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell th...
3 Promising Penny Stocks With Market Caps Under $200M
As major U.S. stock indexes reach new records, driven by anticipation of Federal Reserve decisions and tech earnings, the market continues to capture investor attention with its dynamic shifts. Amidst...
Top Midday Gainers
Rani Therapeutics (RANI) said on Friday that it signed a collaboration and licensing agreement value PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candida...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
